Appendix 4E Preliminary Final Report
Filed with ASX · · 15 pages · English
No dividend has been declared or paid for the year ended 31 December 2025 (31 December 2024: $nil). Brief Explanation of Results During the financial year ended 31 December 2025, Osteopore Limited (Osteopore or the Company) maintained its strategic emphasis on driving top-line expansion while progressing key development and commercialisation initiatives across its regenerative medicine portfolio.
Earlier from Osteopore
- Drawdown of Tranche 2 of the Redeemable Convertible Notes
- OSX secures Latin America deal for craniofacial distribution
- Osteopore Secures Latin America Deal For Craniofacial Distribution
- Further Drawdown of T1 of the Redeemable Convertible Notes
- Activities Report December 2025 and Appendix 4C
Later from Osteopore
- OSX secures distribution for autologous dentin bone graft
- OSX signs agreement for injectable regenerative bone filler
- Clarification - agreement for injectable regen bone filler
- Further Drawdown of T2 of the Redeemable Convertible Notes
- Activities Report March 2026 and Appendix 4C
Follow Osteopore into a list and get an email when it puts out news.
Follow Osteopore